Free Trial
NASDAQ:SPRY

ARS Pharmaceuticals Q1 2025 Earnings Report

ARS Pharmaceuticals logo
$13.49 -0.53 (-3.78%)
Closing price 05/7/2025 04:00 PM Eastern
Extended Trading
$13.87 +0.38 (+2.82%)
As of 08:48 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

ARS Pharmaceuticals EPS Results

Actual EPS
N/A
Consensus EPS
-$0.35
Beat/Miss
N/A
One Year Ago EPS
N/A

ARS Pharmaceuticals Revenue Results

Actual Revenue
N/A
Expected Revenue
$7.48 million
Beat/Miss
N/A
YoY Revenue Growth
N/A

ARS Pharmaceuticals Announcement Details

Quarter
Q1 2025
Time
Before Market Opens
Conference Call Date
Wednesday, May 14, 2025
Conference Call Time
8:30AM ET

Conference Call Resources

Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like ARS Pharmaceuticals? Sign up for Earnings360's daily newsletter to receive timely earnings updates on ARS Pharmaceuticals and other key companies, straight to your email.

About ARS Pharmaceuticals

ARS Pharmaceuticals (NASDAQ:SPRY), a biopharmaceutical company, develops treatments for severe allergic reactions. The company is developing neffy, a needle-free and low-dose intranasal epinephrine nasal spray for the emergency treatment of Type I allergic reactions, including anaphylaxis. It serves healthcare professionals, patients, and caregivers. ARS Pharmaceuticals, Inc. was founded in 2015 and is headquartered in San Diego, California.

View ARS Pharmaceuticals Profile

More Earnings Resources from MarketBeat